This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Posts Profit Rise

Bristol-Myers Squibb (BMY - Get Report) delivered a penny beat for the quarter and nudged adjusted guidance up on Thursday but warned of material restructuring charges to come.

The New York-based drugmaker reported GAAP earnings of $848 million, or 43 cents a share, vs. $338 million, or 17 cents a share, in the year-ago quarter.

Before items, the company earned $764 million, or 38 cents a share, up from $438 million, or 22 cents a share, in the 2006 period. Analysts surveyed by Thomson Financial had expected 37 cents a share on revenue of $5.02 billion.

Bristol said net sales increased 22% to $5.1 billion. The company said the increase reflects growth in key and newer products and the adverse impact of generic drug competition that hurt sales in the comparable 2006 quarter.

Sales of Plavix increased 99% to $1.25 billion and rose 128% in the U.S. Sales in the year-ago quarter suffered from generic competition.

Another sizable sales increase came from the company's Abilify for schizophrenia, acute bipolar mania and bipolar disorder, which rose 34% to $420 million. International sales increased 72% (including a 12% favorable foreign exchange impact) to $91 million. Bristol's revenue for Abilify consists of alliance revenue representing its 65% share of net sales in countries where it copromotes the drug with Otsuka Pharmaceutical.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $67.86 1.30%
AAPL $118.14 -0.14%
FB $106.42 2.10%
GOOG $762.95 2.70%
TSLA $236.10 2.50%


Chart of I:DJI
DOW 17,832.20 +112.28 0.63%
S&P 500 2,093.22 +12.81 0.62%
NASDAQ 5,134.9170 +26.2510 0.51%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs